Written by Catherine Burger
Spoon Feed
Here’s the brief on how to diagnose and treat cyanotic congenital heart disease.
Got the blues
This article reviews the presentation, diagnostic workup, and treatment of critical, cyanotic congenital heart disease (CCHD) including the “five T’s” (truncus arteriosus, dextro-transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total anomalous pulmonary venous return) as well as hypoplastic left heart syndrome, Ebstein’s anomaly, and critical pulmonary stenosis.
While some lesions are mild, only presenting with cyanosis during times of stress, survival with other lesions is dependent on PDA or PFO patency and can present with cyanosis and shock when the PDA closes in the patient’s first weeks of life. Most cases of CCHD are diagnosed on prenatal US or newborn pulse oximetry testing; however, 25% of cases are not discovered until after initial hospital discharge.
Differentiating sepsis and pulmonary pathology from CCHD in the hypoxic, critically ill neonate can be difficult. Key factors that point to CCHD include lack of response to supplemental oxygen, tachypnea without increased work of breathing (so-called silent tachypnea), presence of a murmur, and hepatomegaly (>2cm below the right costal margin). CCHD lesions are often associated with other syndromes; presence of dysmorphic features may also make CCHD more likely.
In addition to infectious workup, neonates with a presentation concerning for CCHD should undergo BNP testing (found to be 100% sensitive and 98% specific in differentiating cardiac vs. pulmonary hypoxia), ECG, CXR, and ECHO. “THE MISFITS” can also be a helpful mnemonic when creating the differential for the critically ill infant.
In addition to cardiopulmonary support and dysrhythmia treatment (Ebstein’s anomaly is particularly associated with dysrhythmias), critically ill, hypoxic infants within the first weeks of life may benefit from prostaglandin E1 (PGE1) infusion (0.05-0.1 micrograms/kg/min). PGE1 infusion should be titrated to oxygenation and effects seen within 30 minutes, with greatest adverse side effects being apnea and hypotension. Proceed with intubation cautiously, as changes in thoracic pressure may lead to cardiovascular collapse.
Additionally, if stress-induced hypoxia due to CCHD is considered (such as a “tet-spell”), maneuvers to decrease pulmonary vascular resistance and increase systemic vascular resistance (knees-to-chest, supplemental oxygen, fentanyl) may improve hypoxia.
For critically ill infants with concern for CCHD, early consultation and transfer, empiric antibiotics, judicious IV fluids and vasoactive/inotropic support (with cardiology consultation) should be considered.
How will this change my practice?
I will look for key features of CCHD in critically ill infants and obtain a BNP when uncertain. I plan to cautiously give IVF and PGE1 as needed and consult pediatric cardiology early, especially when intubation, vasopressors or antiarrhythmics are needed.
Source
High risk and low incidence diseases: Cyanotic critical congenital heart disease. Am J Emerg Med. 2025 Nov 5;100:6-11. doi: 10.1016/j.ajem.2025.11.001. Epub ahead of print. PMID: 41237673.
